Patent: 7,709,610
✉ Email this page to a colleague
Summary for Patent: 7,709,610
| Title: | Therapeutic use of anti-CS1 antibodies |
| Abstract: | The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. |
| Inventor(s): | Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu |
| Assignee: | AbbVie Biotherapeutics Inc |
| Application Number: | US10/982,357 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,709,610
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bristol-myers Squibb Company | EMPLICITI | elotuzumab | For Injection | 761035 | November 30, 2015 | 7,709,610 | 2024-11-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
